ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
ISSN 2383-9457 (ONLINE)
Clinical Outcome for RebyotaTM and VowstTM
| Trial Name (Drug) | Clinical Outcome at 8 weeks | |
|---|---|---|
| PUNCH CD2 (RebyotaTM) | Success rate (%) | 5/44 (56.8%) of the 1 Dose Rebyota+placebo group; p=0.201 25/45 (55.6%) of the 2 Doses Rebyota group; p=0.243; 19/44 (43.2%) of the 2 Doses placebo group; |
| PUNCH CD3 (RebyotaTM) | Bayesian Hierarchical Model 71 % of Rebyota group; 57% of the placebo group; with a posterior probability of superiority of 0.991 |
|
| ECOSPORIII (VowstTM) | CDI recurrence | Recurrence observed in 11/89 (12%) of the Vowst group; 37/93 (40%) of the placebo group; p<0.001 |
| ECOSPORIV (VowstTM) | Recurrence observed in 4/29 (13.8%) of cohort 1; 19/234 (8.1%) of cohort 2 |